Cystoscopy Follow-up After Bladder Cancer: Why Are Checks Needed?
Quick answer
Checks after bladder cancer treatment look for recurrent tumours or changes in disease characteristics. The interval depends on the risk group. Having no symptoms is not enough reason to leave an agreed follow-up programme on your own.
When is the first check?
For non-muscle-invasive Ta/T1 tumours and CIS, the EAU guideline identifies the first cystoscopy three months after TURBT as an important step. Later frequency and overall follow-up duration depend on individual risk. If repeat TURBT or additional treatment is planned, ask the team which procedure and date the schedule is based on; do not change an appointment yourself using this general information.
Is everyone followed up equally often?
No. Low-risk disease differs from high-grade disease, CIS and other high-risk features. After years of clear checks, reduced surveillance may be discussed for some low-risk patients. High-risk patients need long-term follow-up, sometimes lifelong. Another person's timetable may not be suitable for you.
References for this section: EAU. Non-muscle-invasive Bladder Cancer: Follow-up of Patients with NMIBC.
How does the follow-up schedule vary by risk group?
| Risk group | Cystoscopy and cytology framework |
|---|---|
| Low risk | If the 3-month examination is clear: cystoscopy at 12 months, then annually; general duration 5 years. Routine cytology is usually unnecessary. |
| Intermediate risk, excluding the high-grade subgroup | After the 3-month check: cystoscopy every 6 months for 2 years, then annually; general duration 10 years. |
| High / very high risk | Cystoscopy and cytology every 3 months for 2 years, every 6 months until year 5, then annually; long-term, generally lifelong follow-up. |
The high-grade subgroup within intermediate-risk disease is followed as high-risk disease. The starting point and how the timetable relates to repeat TURBT, BCG and new pathology must be clarified in your own record. A date in this general table is not a reason to postpone an existing appointment yourself.
References for this section: EAU. Non-muscle-invasive Bladder Cancer: Follow-up of Patients with NMIBC.
Why reassess follow-up after a recurrence?
A small low-grade recurrence differs from recurrence with T1 or CIS. New pathology, previous treatment and the timing of recurrence may change treatment and surveillance frequency. Before assuming “the same tumour keeps coming back”, check whether the new grade and stage really match previous findings.
The risk model by Sylvester and colleagues combines stage, grade, CIS, tumour number, size and age. Size alone does not determine the group. A recurrence after BCG also cannot be assessed simply by reusing a risk percentage calculated at initial diagnosis.
What happens during a follow-up cystoscopy?
A thin camera passes through the urethra to examine the bladder lining. Flexible and rigid cystoscopy may be used in different settings; anaesthesia or local numbing depends on the procedure. A suspicious area may lead to sampling or a separate treatment procedure. Every check does not mean another TURBT operation is needed.
References for this section: NHS. How a cystoscopy is done. NHS. Tests and next steps for bladder cancer.
Would a urine test or ultrasound be enough?
Tests provide different information. Cystoscopy shows the surface, cytology examines cells shed into urine and imaging helps answer other anatomical questions. Especially in high-risk follow-up, one negative test does not automatically cancel other planned checks. Less invasive surveillance options may be considered for selected patients, but their scope and limitations should be agreed with the clinician.
What does research on fewer cystoscopies show?
The 2025 randomised UroFollow trial studied urine tests and ultrasound in selected low-/intermediate-risk patients after a clear 3-month cystoscopy. It reduced cystoscopy numbers, but some low-grade tumours were missed by testing. It does not show that normal urine tests remove the need for cystoscopy in everyone. Patient selection, the combination of tests and follow-up duration all matter.
DaBlaCa-15 studied a specific urine biomarker alternating with cystoscopy during follow-up of high-grade disease. Procedure numbers fell, but the test also missed high-grade recurrences, and the researchers noted that long-term safety needed longer follow-up. Such strategies are promising; they differ from changing your own plan on the basis of any commercial urine-test result.
References for this section: Schmitz-Dräger BJ, Bismarck E, Roghmann F, et al. Results of the Prospective Randomized UroFollow Trial Comparing Marker-guided Versus Cystoscopy-based Surveillance in Patients with Low/Intermediate-risk Bladder Cancer. Eur Urol Oncol. 2025;8(4):1041-1049. Dreyer T, Brandt S, Fabrin K, et al. Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial. Eur Urol. 2025;88(1):23-30.
When should the upper urinary tract be assessed?
The bladder is only one part of the urinary tract. Upper-tract imaging may be included particularly for high- and very-high-risk patients. CT is not required at every low-risk visit. Kidney function, contrast-related history and earlier findings guide imaging choices. If cytology is positive despite no visible bladder lesion, assessment may need to extend beyond the bladder.
References for this section: EAU. Non-muscle-invasive Bladder Cancer: Follow-up of Patients with NMIBC.
What if an appointment is delayed or new bleeding occurs?
Do not silently leave a missed check until the following year. Give the team your last pathology, BCG and clear-cystoscopy dates and ask for a revised plan. New visible bleeding, persistent burning or a marked change in urinary flow should not be ignored until the routine appointment. Clot-related inability to urinate or marked general deterioration needs urgent assessment.
To address anxiety, ask whether cystoscopy will be flexible or rigid, how local anaesthesia is used, how findings are explained and what happens if biopsy is needed. Tell the team about pain or infection during previous procedures. The aim is not the greatest possible number of procedures, but appropriate, sustainable surveillance for your risk.
References for this section: NHS. How a cystoscopy is done. NHS. Complications of a cystoscopy.
A short checklist before the appointment
- Note the dates of your last TURBT, BCG and other intravesical treatments.
- Report new bleeding, burning, fever or difficulty passing urine.
- Bring a medicine list and earlier pathology and cytology results.
- Ask for a written plan for results, the next check and symptoms that need earlier contact.
Which symptoms after the procedure should not wait?
Brief mild burning may follow cystoscopy. Contact the healthcare team for fever, significant deterioration, increasing pain, heavy bleeding or inability to pass urine. Check the procedure instructions for how long symptoms are expected to last. A distant routine follow-up date does not mean you should wait if a new problem develops.
References for this section: NHS. Complications of a cystoscopy.
Frequently asked questions
Can I skip a cystoscopy check if there is no blood in my urine?
Having no symptoms alone does not make the check unnecessary. A clinician should assess timetable changes in light of your risk and previous findings.
Are recurrence and progression the same?
Recurrence means the disease is detected again. Progression means worsening characteristics, such as a more advanced stage. Not every recurrence carries the same risk; the new pathology matters.
Are checks still needed after BCG finishes?
Yes. Completing BCG does not remove the need for follow-up. Later assessments are planned according to individual risk and treatment response.
Sources
- EAU. Non-muscle-invasive Bladder Cancer: Follow-up of Patients with NMIBC [Internet]. Available from: https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer/chapter/followup-of-patients-with-nmibc
- National Cancer Institute. Bladder Cancer Diagnosis [Internet]. Available from: https://www.cancer.gov/types/bladder/diagnosis
- NHS. Tests and next steps for bladder cancer [Internet]. Available from: https://www.nhs.uk/conditions/bladder-cancer/tests-and-next-steps/
- NHS. How a cystoscopy is done [Internet]. Available from: https://www.nhs.uk/tests-and-treatments/cystoscopy/how-its-done/
- NHS. Complications of a cystoscopy [Internet]. Available from: https://www.nhs.uk/tests-and-treatments/cystoscopy/complications/
- European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. Eur Urol. 2021;79(4):480-488. doi:10.1016/j.eururo.2020.12.033 · PubMed
- Results of the Prospective Randomized UroFollow Trial Comparing Marker-guided Versus Cystoscopy-based Surveillance in Patients with Low/Intermediate-risk Bladder Cancer. Eur Urol Oncol. 2025;8(4):1041-1049. doi:10.1016/j.euo.2025.04.020 · PubMed
- Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial. Eur Urol. 2025;88(1):23-30. doi:10.1016/j.eururo.2025.03.018 · PubMed
Keep reading:
Related patient guides
Negative or Atypical Urine Cytology: How Should Results Be Interpreted?
Does urine cytology rule out cancer? Understand negative, atypical and suspicious findings and how they relate to culture, cystoscopy and other urine tests.
BCG Treatment for Bladder Cancer: What Happens, Side Effects and Warning Signs
Who may receive intravesical BCG, how is it given and how long does it last? Understand side effects, reasons to postpone treatment and urgent warning signs.
Why Might a Second TURBT Be Needed After Bladder Tumour Resection?
Why is repeat TURBT recommended after bladder tumour surgery? Learn about residual tumour, staging, timing and decisions after pathology.